Serum Histone Succinylation: A Predictive Biomarker for Malignant Solid Tumors
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,000
- 主要终点
- Evaluate the positive rate of serum histone succinylation in patients with malignant solid tumors
研究概览
简要总结
In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis.
This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.
详细描述
Primary Objective To evaluate differential expression of serum histone succinylation between malignant solid tumor patients and healthy controls, thereby validating its early detection value.
Secondary Objectives
To determine correlations between serum histone succinylation levels and:
Tumor types Tumor stages
To statistically analyze associations of serum histone succinylation with:
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Case Group:
- •Aged ≥18 years, regardless of sex；
- •Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy；
- •Control Group:
- •Aged ≥18 years, regardless of sex；
- •Non-cancer participants enrolled through health screenings；
排除标准
- •Pregnant individuals；
- •Individuals with serious mental disorders or communication barriers；
- •Other conditions deemed by investigators to contraindicate study participation；
结局指标
主要结局
Evaluate the positive rate of serum histone succinylation in patients with malignant solid tumors
时间窗: 2025.08.01-2026.12.31
Evaluate the positive rate of serum histone succinylation in malignant solid tumor patients versus healthy individuals through Western blot analysis, quantify the percentage difference between the two groups, and thereby validate its potential for early cancer screening
次要结局
- Define the relationship between histone succinylation modifications in serum and different tumor types as well as tumor staging(2025.08.01-2026.12.31)
研究者
Yinghua Ji
Doctor
The First Affiliated Hospital of Xinxiang Medical College